柳氮磺胺吡啶联合中药灌肠治疗溃疡性结肠炎的疗效及其对血清白介素-2和C-反应蛋白的影响研究

Efficacy of Salicylazosulfapyridine Combined with Herbal Coloclysis in the Treatment of Patients with Ulcerative Colitis and Its Effect on Interleukin-2 and C-reactive Protein

目的观察柳氮磺胺吡啶联合中药灌肠治疗溃疡性结肠炎患者的疗效及其对血清白介素-2(IL-2)、C-反应蛋白(CRP)的影响。方法回顾性分析2008年1月—2010年12月我院溃疡性结肠炎患者118例,其中58例采用口服柳氮磺胺吡啶治疗,6.0 g/次,3次/d,15 d后减量至4.5 g/次,3次/d,为对照组。另60例患者在对照组基础上加用自拟中药煎剂保留灌肠,1次/d,为研究组。两组疗程均为20 d,对比两组的临床疗效以及治疗前后血清IL-2、CRP水平的变化。结果研究组的疗效明显优于对照组,差异有统计学意义(u=-3.464,P<0.001)。与治疗前比较,治疗后两组患者的血清IL-2水平明显升高、CRP水平明显下降,差异有统计学意义(P<0.05);且治疗后研究组血清IL-2、CRP水平与对照组比较差异有统计学意义(P<0.05)。结论柳氮磺胺吡啶联合中药灌肠治疗溃疡性结肠炎的疗效优于单用柳氮磺胺吡啶治疗,其机制可能与血清IL-2水平升高、CRP水平降低有关。

Objective To investigate the efficacy of salicylazosulfapyridine combined with herbal coloclysis in the treatment of ulcerative colitis and its effect on serum interleukin -2 （IL- 2） and C -reactive protein （CRP）. Methods The clinical data of 118 patients with ulcerative colitis admitted to our hospital from January 2008 to December 2010 were retrospec-tively analyzed. They were randomly divided into two groups： control group （n =58）, in which patients were given oral salicy- lazosulfapyridine treatment （6. 0 g, tid; reduced to 4. 5 g, tid, after 15 days） ; and treatment group （n =60）, in which pa- tients were given herbal coloclysis qd in addition to the oral salicylazosulfapyridine treatment. Treatment in each group lasted both20 days. The changes of IL - 2 and CRP levels were compared before and after treatment. Results The efficay was significantly superior in the treatment group than in the control group （u = -3.464, P 〈 0. 01 ）. In both groups, the IL- 2 levels were in- creased significantly after treatment, and the CRP levels were decreased significantly after treatment （ P 〈 0. 05 ）. The IL - 2and CRP levels of the treatment group were significantly better than those of the control group （P 〈 0. 05 ）. Conclusion The salicylazosulfapyridine combined with herbal coloclysis shows good efficacy in treating ulcerative colitis, which may be achieved by influencing the change of serum IL - 2 and CRP.